Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: June 7, 2006
Last updated: December 18, 2013
Last verified: March 2009

RATIONALE: Endoscopic surgery is a less invasive type of surgery for laryngeal cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether endoscopic surgery is more effective than radiation therapy in treating laryngeal cancer of the glottis.

PURPOSE: This randomized phase II trial is studying endoscopic surgery to see how well it works compared with radiation therapy in treating patients with stage 0, stage I, or stage II laryngeal cancer of the glottis.

Condition Intervention Phase
Head and Neck Cancer
Procedure: endoscopic surgery
Procedure: laser surgery
Radiation: radiation therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Early Stage Glottic Cancer: Endoscopic Excision or Radiotherapy [EaStER]

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Feasibility [ Designated as safety issue: No ]
  • Patient acceptability [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Voice analysis [ Designated as safety issue: No ]
  • Quality of life [ Designated as safety issue: No ]
  • Economic assessment [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: September 2005
Study Completion Date: July 2006
Detailed Description:


  • Determine the feasibility of conducting a large phase III randomized study in the future, comparing radiotherapy vs endoscopic excision in patients with stage 0-II laryngeal cancer of the glottis.
  • Determine patient acceptability of the proposed trial design.
  • Compare the effect of using dedicated head and neck research nurses vs general nurses on patient recruitment.
  • Refine outcome measures, including voice analysis and quality of life.

OUTLINE: This is a randomized, controlled, multicenter, pilot study. Patients are stratified according to participating center and T stage (Tis or T1 vs T2a). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo endoscopic excision via CO_2 laser or cold steel.
  • Arm II: Patients undergo radiotherapy once daily, 5 days a week, for 3-4 weeks. Patients undergo vocal analysis at baseline and at 6 months and 1 and 2 years after randomization.

Quality of life is assessed at baseline, at 1 year, and then annually for 5 years.

After completion of study treatment, patients are followed periodically for up to 5 years.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed squamous cell carcinoma of the glottic larynx, including tumors at the anterior commissure

    • Stage 0-II (Tis, T1, or T2a)
  • No clinical or radiological sign of nodal involvement
  • No evidence of distant metastases
  • Airway anatomy suitable for endoscopic excision


  • Fit to receive radical treatment as either radiotherapy or endoscopic excision
  • Life expectancy ≥ 2 years
  • No other cancer in the past 10 years except basal cell carcinoma of the skin or adequately treated carcinoma in situ of the uterine cervix
  • No vasculitic conditions adversely affecting radiotherapy
  • No other co-existing medical condition that would limit life expectancy
  • Not pregnant


  • No concurrent chemotherapy
  • No concurrent palliative treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00334997

United Kingdom
Southmead Hospital
Bristol, England, United Kingdom, BS10 5NB
Aintree University Hospital
Liverpool, England, United Kingdom, L9 7AL
Clatterbridge Centre for Oncology
Merseyside, England, United Kingdom, CH63 4JY
James Cook University Hospital
Middlesbrough, England, United Kingdom, TS4 3BW
Norfolk and Norwich University Hospital
Norwich, England, United Kingdom, NR4 7UY
Royal Infirmary - Castle
Glasgow, Scotland, United Kingdom, G4 0SF
Sponsors and Collaborators
University College London Hospitals
Study Chair: Martin A. Birchall, MD Southmead Hospital
  More Information

No publications provided Identifier: NCT00334997     History of Changes
Other Study ID Numbers: CDR0000478790, CRUK-BRD/05/024, EU-20611, CRUK-EASTER, ISRCTN17541410
Study First Received: June 7, 2006
Last Updated: December 18, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I squamous cell carcinoma of the larynx
stage II squamous cell carcinoma of the larynx
stage 0 laryngeal cancer

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site processed this record on November 20, 2014